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Abstract 
 Objectives 
To determine whether baseline and on- statin C-reactive protein (CRP) are independent predictors 
of cardiovascular (CV) outcome beyond LDL-cholesterol (LDL-c). 
Background 
Use of CRP as a predictor of statin treatment remains controversial 
Methods  
We investigated the relationship of baseline and on-treatment CRP with subsequent CV events in 
Cox models using a subset of white subjects with no previous history of CV disease from the UK 
Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). 
Results 
During 5.5 years of follow-up, a total of 488 subjects experienced a CV event. CV risk increased 
with loge baseline CRP [HR per one standard deviation 1.21 (95% CI: 1.09,1.33) in an adjusted 
model. In ASCOT-LLA, the relative statin effect in preventing CV events did not differ according to 
tertiles of baseline CRP (p=0.69).  After 6 months atorvastatin, median LDL-c and CRP were 
reduced by 38.7% and 25.8% respectively. Those who achieved LDL-c below the median, had a 
reduced CV risk (HR 0.58 [CI 0.34, 0.97]) compared with those who did not. In contrast those who 
achieved a CRP level below the median did not have a reduced risk of CV (HR 0.95[CI 0.59, 1.55]). 
Amongst those who achieved an LDL-c below the median, there was no difference in CV risk 
whether they also achieved a CRP level below (HR 0.55[CI 0.30,1.02]) or above the median (HR 
0.56 [CI 0.30,1.03]).   
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Conclusion 
In these primary prevention patients, although baseline CRP independently predicted CV risk, 
achieved CRP on statin therapy did not predict CV events either alone or in combination with 
 LDL-c. 
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Abbreviations 
 
ASCOT = Anglo-Scandinavian Cardiac Outcomes Trial 
ASCOT-BPLA = Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm 
ASCOT-LLA = Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm 
BMI = body mass index 
CRP = C-reactive protein 
CVD = cardiovascular disease 
CHD = coronary heart disease 
CI = confidence interval 
FHCHD = family history of coronary heart disease 
HDL = high density lipoprotein  
HR = heart rate 
LDL = low density lipoprotein 
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Introduction  
That inflammation plays an important role in the pathophysiology of atherosclerosis is undisputed 
(1,2,3).   Moreover, various molecular and cellular components of the inflammatory response are 
activated and may contribute to plaque rupture and the presentation of acute coronary 
syndromes (4).  Therefore the study of biomarkers of inflammation, notably C-reactive protein 
(CRP) and serum amyloid A, has been a focus of interest for many authors (5,6).  Indeed CRP has 
been proposed, and in some places used, as a clinical tool for cardiovascular disease (CVD) risk 
prediction scores (7,8,9), yet there remains disagreement regarding its clinical utility, beyond that 
achieved with conventional biomarkers (10).  There has also been notable debate over whether 
statin-associated CRP reduction is an independent predictor of CVD after consideration of 
concomitant LDL-cholesterol (LDL-c) reduction (11,12). 
We have previously reported, using a nested case-control design, from the Anglo-
Scandinavian Cardiac Outcomes Trial (ASCOT) in hypertensive patients selected on the basis of 
traditional risk factors, that CRP did not usefully improve the prediction of CV events and, critically, 
that reduction in CRP associated with statin therapy was not a predictor of CV outcome alone or in 
combination with LDL-c (12).  One criticism of our findings was based on the relatively small 
number of patients in whom on-treatment levels of CRP were available (11), partly a consequence 
of the matched case-control methodology. Therefore, in order to address these concerns by 
increasing statistical power and to limit potential bias, we have now extended our observations to 
include a full cohort analysis of all eligible white patients in the UK and Ireland recruited into the 
Lipid-Lowering Arm of the ASCOT trial (ASCOT-LLA) from whom baseline and on-treatment values 
of CRP were obtained.  Our hypothesis, was that on- treatment CRP would not meaningfully 
predict subsequent CVD events, whereas LDL-c was strongly and significantly predictive.  
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Methods 
A cohort study based on subjects recruited into ASCOT-LLA cohort was used to determine the 
association between baseline CRP and subsequent CV outcomes.  In separate analyses we 
assessed whether CRP levels following six months treatment with atorvastatin 10mg were 
independent predictors of CV outcomes. For the purpose of the present study, those with any 
history of prior CV disease were excluded.  
 
Patients and recruitment 
The detailed ASCOT protocol has been published previously (13) and further information is 
available at http://www.ascotstudy.org.  Hypertensive patients, with three or more other risk 
factors for CVD but no history of prior myocardial infarction (MI) or currently treated angina were 
eligible.  
In the Blood Pressure- Lowering Arm of the ASCOT trial (ASCOT-BPLA), 9098 patients were 
randomised in the UK and Ireland to either amlodipine adding perindopril as required (amlodipine-
based) or atenolol adding bendroflumethiazide as required (atenolol-based).  
In addition to  randomisation into ASCOT-BPLA, those with a fasting total cholesterol of 
<6·5mmol/L (250mg/dl) were further randomised, using a factorial design, to either 10mg 
atorvastatin daily or matching placebo (ASCOT-LLA).  
ASCOT-LLA was stopped prematurely after a median follow up of 3·3 years owing to highly 
significant benefits in favour of atorvastatin over placebo on the primary coronary endpoint. All 
patients in ASCOT-LLA were offered open label atorvastatin and continued in the ASCOT-BPLA 
until its termination after a median 5·5 years follow up. 
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Baseline characteristics of participants and primary outcomes of each arm of the trial have 
previously been reported (13,14,15).  In the current analyses only white patients with no history of 
CVD were included from both ASCOT- LLA and BPLA combined. 
 
CV outcomes 
The major CV outcome evaluated in analyses was a composite of fatal coronary heart disease 
(CHD), symptomatic non-fatal MI, coronary revascularisation, fatal and non-fatal stroke, occurring 
in the UK and Ireland among participants in the ASCOT – LLA study, between February 1998 and 
October 2005.  During the median follow-up period of 5·5 years, 488 CV outcomes were reported. 
In addition, associations with CHD events (fatal coronary heart disease (CHD), symptomatic non-
fatal MI, coronary revascularisation) and stroke events were also investigated where numbers 
permitted. 
 
Laboratory methods  
Fasting lipids were routinely measured annually during the trial (www.ascotstudy.org). CRP 
samples were collected at baseline and after six months, and subsequently all stored serum 
samples were measured by a high sensitivity method, on an Abbott Architect, by technicians 
blinded to the CV outcome status of the participants’ samples. The lower limit of sensitivity was 
0·1mg/L and coefficient of variation <4%. 
 
Statistical Analysis 
Continuous data are presented as mean and standard deviation (SD) or median and interquartile 
range (IQR), and categorical variables, as proportions.  Baseline characteristics were compared by 
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event or no-event groups using t-tests, chi-square tests for proportions, and non-parametric 
Mann-Whitney tests for skewed data.  Age- and sex- adjusted Spearman correlation was used to 
assess the correlation between baseline CRP and baseline clinical characteristics.  For a given 
sample size of 3987 subjects with 456 CV events, the study had at least 90% power to detect a 
hazard ratio of 1.20 per SD increased in loge CRP. Analyses were performed on an intention-to-
treat basis, and person-time was calculated until the first confirmed CV endpoint or to the end of 
the trial if no endpoint occurred.  Kaplan-Meier curves were used to estimate cumulative 
incidence over time by baseline CRP tertile groups, and the log-rank test was used to compare 
survival curves.   The association between CRP and the risk of each of CHD or stroke event was 
reported as a hazard ratio (HR) obtained from a Cox proportional hazard regression model, first by 
treating loge transformed baseline CRP as a continuous variable giving the risk of having an event 
per 1 SD change with 95% confidence intervals (CI) and secondly, by categorizing CRP into tertiles 
with the lowest as a reference.  Two models were used to examine the association between 
baseline CRP and risk of CVD: Model 1: adjusted for age and sex; Model 2: adjusted for age, sex, 
current smoking status, diabetes mellitus, left ventricular hypertrophy, baseline systolic blood 
pressure (SBP), total- and HDL- cholesterol (HDL-c), randomized statin drug assignment, 
randomized blood pressure drug assignment, body mass index (BMI), fasting glucose, family 
history of CHD (FHCHD), creatinine, and educational attainment.  However, two different models 
were used in the on-treatment CRP analyses: Model 1: adjusted for age, sex, loge baseline CRP, 
Model 2: adjusted for age, sex, current smoking status, diabetes mellitus, left ventricular 
hypertrophy, baseline SBP, total- and HDL- c, randomized atorvastatin/placebo, randomized blood 
pressure drug assignment, BMI, fasting glucose, FHCHD, creatinine, educational attainment , loge 
baseline CRP and LDL-c.   The assumption of proportionality was tested with Schoenfield’s 
residuals.  To test for effect modification by CRP tertiles, we included interaction terms between 
CRP or LDL-c tertile indicators and randomized assignment in the models.  Because of the small 
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number of subjects (n=47: 26 on placebo and 21 on atorvastatin) with stroke outcomes in ASCOT-
LLA, with complete data on both CRP, LDL-c, and covariates, we only reported the on-treatment 
effect on CVD and on CHD.   
 To investigate the predictive effect of baseline CRP and LDL-c on CVD and CHD, analyses 
used UK ASCOT-LLA and BPLA combined datasets, whereas for the on-treatment analyses we 
restricted analyses to those who participated in ASCOT-LLA.   On treatment CRP/LDL-c levels were 
treated as time dependent covariates in these analyses. 
Two sensitivity analyses were performed to assess the consistency of our results. Analysis 
on the association between baseline CRP and each endpoint was repeated on those who were not 
assigned atorvastatin. The second used imputed data for missing data values in order to repeat 
on-treatment CRP analyses.  
Ten imputed datasets were created using Rubin’s rules (16) to combine effect estimates 
and estimate standard errors to allow for the uncertainty caused by missing data.   Multiple 
imputation allows inclusion of subjects with incomplete data in analyses and makes full use of all 
the available data, increasing power and precision.  Multiple imputation was undertaken using ICE 
(Imputation by Chained Equation) in Stata.  
We further performed a post-hoc analysis to investigate the association between on-
treatment non-HDL-c and CV and CHD events. 
   Analyses were conducted using SAS version 9.1 (SAS Institute, Cary, NC) and Stata version 
11 (StataCorp, College Station, TX), using two-sided tests with a significance level of <0.05. 
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Results 
Baseline characteristics 
In total 488 subjects with an event and 3797 with no event during follow-up in ASCOT-LLA and 
ASCOT-BPLA were included in the analyses of predictive values of baseline CRP (Figure 1).  The 
mean age was 64.3±8.1 years and 85.6% were male.  A comparison of the baseline characteristics 
between those who developed an event and those who did not, demonstrated that those who did 
had a generally worse clinical profile (Table 1). 
Baseline CRP was positively correlated with total cholesterol, LDL-c, triglycerides and BMI 
but negatively with HDL-c in both groups (Table S1). 
 
Baseline CRP and risk of subsequent cardiovascular events   
The risk of developing a CV event and CHD alone increased with baseline CRP (Table 2).  Baseline 
CRP was not, however, significantly associated with risk of stroke alone, although there were 
trends towards a positive association.  The hazard ratio for CV events was 1.21 (1.09, 1.33; 
p=0.0003) per 1 SD increased in loge-transformed CRP, after adjusting for classical risk factors and 
randomisation.  Similar results were noted in the analyses by tertiles of CRP (Table 2, Figure 2).  
Similar results were observed in a sensitivity analysis of subjects who were not assigned 
atorvastatin (Table S2). 
 
Statin efficacy effect by baseline CRP  
There was no evidence of an interaction between baseline LDL-c or CRP and treatment effect 
(statin/placebo or atenolol/amlodipine-based treatment) on CV events or CHD or stroke; 
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specifically the statin effect in preventing CVD did not differ significantly according to the tertiles 
of baseline CRP (p>0.60; Table S3).  
 
Achieved CRP and LDL-c at 6 month and risk of cardiovascular event 
After 6 months of atorvastatin the median LDL-c was reduced by 38.7% [3.46 mmol/L (IQR (2.96, 
3.95) to 2.12 (1.74, 2.56)], while in the placebo group the median fell by 1.7% [from 3.46 mmol/L 
(2.99, 3.96) to 3.40 (2.86, 3.92); comparing change, p<0.0001].  The concomitant changes for CRP 
were 25.8% reduction on atorvastatin [from 2.21 mg/L (1.12, 4.63) to 1.64 mg/L (0.82, 3.43) 
compared with 0.4% in the placebo group [from 2.25 mg/L (1.09, 4.4) to 2.24 mg/L (1.13, 4.48); 
p=0.02].  The Spearman correlation between the percentage change in CRP and the percentage 
change in LDL-c was modest (r=0.12, p<0.0001).  
Changes in LDL-c or CRP from baseline to 6 months were normally distributed. Irrespective 
of treatment group assignment in the ASCOT-LLA cohort, a 1 mmol/L decrease in LDL-c between 
baseline and 6-months in-trial treatment was associated with a 17% (HR 0.83 (0.69, 0.99); p=0.04) 
and a 17% (HR 0.83 (0.67, 1.02); p=0.07) risk reduction in CV and CHD events respectively, after 
adjustment for baseline levels, age and sex. These estimated effects were essentially unchanged 
after multiple adjustments for other risk factors, but were no longer significant (HR 0.86 [0.66, 
1.12], 0.87 [0.63, 1.19] respectively)).  In contrast, the effect of a 10 mg/L decrease in CRP showed 
no evidence of an association with CV or CHD events (HR 1.03 (0.90, 1.18), p=0.69 for CV; 1.05 
(0.92, 1.20), p=0.48 for CHD).  Those who did not achieve CRP below the median value at 6-
months in either the placebo (median: 2.24mg/L) or atorvastatin (median: 1.64mg/L) groups, did 
not have a significantly altered risk of CV or CHD events compared with those who did (Table 3).  
12 
 
Similar analyses were repeated using a separate imputed dataset. In this dataset, the 
multivariable analyses (Model 4) showed that the HRs for CV  were similar to those reported in the 
complete case analysis of Table 3 (Table S4).   
After adjusting for risk factors (including baseline CRP and LDL-c) subjects allocated to 
atorvastatin had a non-significant 19-22% reduced risk of CV events regardless of whether they 
achieved a CRP less than the median of 1.64 mg/L (Figure 3, Table 4).  In contrast, those who 
achieved LDL-c below the median had a significant 46% reduction in risk of CV events (HR 0.54 
(0.34, 0.85); p=0.008) in the multivariable-adjusted analysis.  Within the atorvastatin group, those 
who achieved LDL-c below median had a 42% reduced risk compared with those who did not (HR 
0.58 (0.34, 0.97), p=0.04) (Model 2 in Table 4).  Similar results were also noted in the CHD analyses 
(Figure 3, Table 4).   Post-hoc analyses of on-treatment non-HDL, showed similar significant results 
(data not shown).     
On-treatment CRP and LDL-c analyses were repeated using a dataset including imputed 
data for missing data.  A significant treatment effect for CHD (39% risk reduction) was observed in 
those who achieved CRP below median.  However, in contrast to findings for achieved LDL-c there 
was, once again, no significant within atorvastatin group difference for achieved CRP below, versus 
above, the median [HR 0.75 (0.43,1.32) p=0.32].  Overall the effect estimates of on-treatment CRP 
and LDL-c on CV and CHD events were similar to those reported in the complete case analyses 
(Table 5).   
Compared with placebo, the lowest risk of CV events was noted in subjects allocated to 
atorvastatin who achieved LDL-c below the median level (<2.1mmol/L) irrespective of on-
treatment CRP levels. (Figure 4, Table 6,)  A significantly lower risk of CHD was noted in subjects 
taking atorvastatin who achieved low LDL-c but had a high level of on-treatment CRP (Figure 5, 
13 
 
Table 6). However this result was based on 6 subjects with an event.    Sensitivity analyses using 
imputed data showed similar results (Figure 6).  
We conducted additional analyses using alternative cut-offs such as CRP above and below 
2mg/L and either LDL-c above and below 2.59mmol/L (100mg/dl) or non-HDL-c above and below 
3.37mmol/L (130mg/dl). In neither of these analyses was there an additional benefit to be gained 
by lowering CRP to below 2mg/L (data not shown). 
 
Discussion 
We report in this trial of hypertensive patients at modest risk of future CV events, that baseline 
CRP independently predicted subsequent CV events but neither baseline levels of CRP nor the 
achieved levels of CRP on-treatment with atorvastatin, 10mg, predicted the efficacy of the statin in 
preventing future CV events. The results of this cohort analysis are similar but more robust than 
those we reported from an earlier nested case-control study derived from the same population 
(12). 
 Several studies have shown that baseline CRP is an independent risk predictor for CV 
events and this has been confirmed in a recent meta-analysis (6) such that predictive benefits are, 
at best, modest (9).  Whilst, there remains uncertainty about the relative benefit of CRP to risk 
prediction, the strength of the association, particularly when potential confounders are 
incorporated into the models, is weak (6). We also confirm in this study that there was no 
interaction between baseline values of CRP and the relative effect of the statin on CV events. 
These findings are consistent with those reported from the Heart Protection Study (17), PROSPER 
(18) and JUPITER (19). 
14 
 
Arguably the most controversial and debateable issue concerns the extent to which on-
treatment levels of CRP predict the benefits of CV outcome associated with statin therapy. This 
has been proposed based on analyses from observations of on-treatment levels of CRP from a 
number of trials, many of which recruited high risk individuals (20,21,22) and, particularly, JUPITER 
which recruited low risk individuals with high CRP (19).  
It has been suggested that data from our earlier nested case-control study in ASCOT-LLA 
showed that those who achieved lower levels of on-treatment CRP had a 25% greater relative risk 
reduction in CV events, and that our results were actually compatible with other studies (11).  
There are flaws in this argument.  First, when controlling for confounding variables including CRP 
and LDL-c at baseline, the absolute difference in risk was 12% (not 25%) (12).  Further, those who 
did not achieve median CRP reduction had an increased risk of 14% in the ASCOT case-control 
study, with figures of 5% and 12% increased risk in the analyses using complete-case data and 
imputed data respectively in the present study. These estimates appear appreciably different to 
the 47%, 33%, and 26% increased risk reported in JUPITER (19), A to Z (21), and PROVE-IT (20) for 
similar comparisons.  Regardless of treatment group assignment in ASCOT, a 1 mmol/L decrease in 
LDL-c was shown to be associated with a significant 17% reduced risk of CV and CHD events.  A 
reduction in CRP, however, did not have any association with CV outcome in the ASCOT-LLA 
population, once reduction of LDL-c was taken into account.  Unless the argument is being made 
that statins are in fact primarily anti-inflammatory drugs (rather than cholesterol reducing drugs) 
selective or even additional reporting of the risk reduction association with CRP lowering appears 
of minimal benefit in delineating the impact of statins on CV risk.  Figure 4 clearly shows that once 
achieved LDL-c is considered, further stratification by achieved CRP has little bearing on the 
relative risk of CV events. Because about half the patients recruited into ASCOT-LLA could be 
categorized as having the metabolic syndrome, thus sharing some characteristics with the JUPITER 
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population, we conducted a post hoc subgroup analysis on these patients.  Compared with those 
in the placebo group, among those with metabolic syndrome, those who were assigned to 
atorvastatin and had a higher on-treatment LDL-c, and tended to have higher risk of CVD 
regardless of their on-treatment CRP levels.   However, those with lower on-treatment LDL-c and 
lower on-treatment CRP  had a non-significant 35%  reduced risk of CVD but there was no 
evidence of interaction between metabolic syndrome and on-treatment CRP & LDL-c levels on 
CVD.   Such analyses should be interpreted with caution, however, owing to limited number of 
events in individual subgroups. 
A further commentary on our earlier findings from the case-control study was made on 
grounds of inadequate power (11).  The current study reports on 456 CV events in total, and for 
the on-treatment CRP analysis 97 events (with imputed data).  This compares with 103 CV events 
in JUPITER for the on-treatment analysis (19).  Moreover, the JUPITER primary CV endpoint 
definition included hospitalisation for angina, which in the ASCOT CV definition was not 
considered as a hard endpoint and therefore not included. We therefore believe that the power of 
both studies is comparable. We have, however, subsequently conducted a further analysis 
incorporating 11 cases of development of unstable angina as a CV endpoint. This made no 
difference to our original conclusion that those achieving lower levels of LDL-c had lower risk of CV 
events regardless of achieved level of CRP. 
Our results showing that on-treatment CRP has virtually no predictive value are in accord 
with the TNT study (23), and CARDS (unpublished data) but contrast with other trials performed 
on patients with  acute coronary syndrome (20,21),  and  patients with angiographically 
documented coronary disease (20).  Investigators have previously claimed that lower levels of CRP 
following statin therapy predict greater subsequent relative risk reductions in CV events 
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(19,20,21,22).    Unfortunately none of these studies except REVERSAL (22) reported the 
relationship of change in CRP (from baseline to follow-up) with events.   
Strengths and limitations of the present study require consideration. The relative merits of 
primary endpoints and power of studies reporting on treatment CRP and CV events are discussed 
above.  The present study reports objectively imputed data, although these results are entirely 
consistent with results from non-imputed data.  In terms of relative generalisability, PROVE-IT (20) 
and A to Z (21) recruited high risk patients with previous acute coronary events.  REVERSAL 
recruited patients with at least 20% stenosis on coronary angiography and with mean baseline LDL 
of 3.9 mmol/L and geometric mean CRP of 2.9 mg/L (22).  JUPITER recruited relatively healthy 
patients with low LDL-c (<3.4 mmol/L) but high CRP (≥2 mg/L) (19), whereas the ASCOT cohort in 
these analyses included patients without any previous history of CV and with median LDL-c of 
3.6mmol/L and median CRP of 2.4 mg/L at baseline.   It is possible that CRP may have different 
predictive ability in different patient types.  However, we believe that, to date, ASCOT data most 
usefully reflects patients commonly seen in primary care. 
In conclusion, our results challenge the need to measure CRP to guide statin dose changes. 
These clinical decisions appear usefully informed by change in LDL-c while on statin treatment, in 
line with the pharmacological role of statins in cholesterol reduction. 
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Table and Figure Legend   
Table 1 – Baseline characteristics of white study population with baseline CRP measurement by 
event status. 
Table 2 –  Hazard ratios (95% CI) of cardiovascular event (coronary heart disease (CHD) or stroke) 
in relation to loge baseline CRP (per SD increase in Log-transformed CRP and in CRP tertiles) among 
all white subjects with no previous cardiovascular disease (CVD). 
Table 3 –  Association between CRP value above median at 6-months and cardiovascular disease 
(CVD) and coronary heart disease (CHD) in relation to CRP of less than median value by 
atorvastatin and placebo. 
Table 4 – Hazard ratios for cardiovascular disease (CVD) and coronary heart disease (CHD) 
associated with achieved level of CRP or LDL-c at 6-months relative to placebo. 
Table 5   –  Hazard ratios for cardiovascular disease (CVD) and coronary heart disease (CHD) 
associated with achieved level of CRP at 6-month relative to placebo using imputed data. 
Table 6   –  Hazard ratios for cardiovascular disease (CVD) and coronary heart disease (CHD) 
according to achieved levels of CRP and LDL-cholesterol after 6-months on atorvastatin.  
Figure 1 –  ASCOT C-reactive protein cohort trial profile. 
Figure 2 –  Cumulative probability of CVD events according to concentration of CRP at baseline. 
Figure 3 –  Multiple adjusted hazard ratios for CVD and CHD events according to achieved level of 
CRP or LDL-cholesterol at 6-months. 
Figure 4 –  Hazard ratios for CV events according to achieved LDL-cholesterol and CRP after 6-
months of atorvastatin. 
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Figure 5 –  Multiple adjusted hazard ratios for CHD events according to achieved LDL-cholesterol 
and CRP after 6-months of atorvastatin. 
Figure 6 –  Multiple adjusted hazard ratios for CVD and CHD events according to achieved level of 
LDL-cholesterol  and CRP at  6-months using imputed data. 
 
Supplementary Tables 
Table S1 – Age and sex adjusted Spearman correlation coefficients of baseline hsCRP with baseline 
clinical characteristics. 
Table S2 – Hazard ratios (95% CI) of cardiovascular event (coronary heart disease (CHD) or stroke) 
in relation to baseline CRP (per SD increase in Log-transformed CRP and in CRP tertiles) among 
white subjects who were not on statin and with no previous cardiovascular disease (CVD). 
Table S3 – The risk of cardiovascular disease (CVD), coronary heart disease (CHD) and stroke in 
each tertile of baseline CRP in the atorvastatin-assigned group compared to the placebo group. 
Table S4 –  Association between CRP value above median at 6-months and cardiovascular disease 
(CVD) and coronary heart disease (CHD) or less than median value by atorvastatin and placebo 
using imputed data. 
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    Table 1:  Baseline characteristics of white study population with baseline CRP measurement by event  
                     status 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
Values are mean (SD) or n (%) 
*  meidan (inter-quartile ) p-values based on Wilcoxon tests   
 
§  3431 subjects participated in lipid-lowering arm  
 Event Status  
Without 
(n=3797) 
With  
(n=488) p_value 
Male 3258 (85.8%) 412 (84.4%) 0.41 
Age (Years) 64.21 (8.09) 65.35 (7.83) 0.003 
Current Smokers 946 (24.9%) 128 (26.2%) 0.53 
Alcohol: Never 831 (21.9%) 125 (25.6%)  
Alcohol: ≤14/21 units/week 2248 (59.2%) 271 (55.5%)  
                >14/21 units/week 718 (18.9%) 92 (18.9%) 0.16 
Completed Education Age: ≤12 1151 (30.3%) 185 (37.9%)  
                                             ≤15 1898 (50.0%) 232 (47.5%)  
                                             ≤18 425 (11.2%) 47 (9.6%)  
                                             >19 323 (8.5%) 24 (4.9%) 0.001 
SBP (mmHg) 162.34 (17.31) 164.65 (17.84) 0.01 
DBP (mmHg) 92.84 (9.80) 92.98 (10.36) 0.76 
Heart Rate (bpm) 70.26 (12.23) 69.68 (12.89) 0.33 
BMI (Kg/m2) 29.16 (4.84) 28.69 (4.06) 0.04 
Total Chol (mmol/L) 5.67 (0.93) 5.98 (1.06) <0.0001 
LDL (mmol/L) 3.60 (0.84) 3.90 (0.96) <0.0001 
HDL (mmol/L) 1.29 (0.34) 1.26 (0.34) 0.07 
Triglyceride (mmol/L)* 1.5 (1.10, 2.10) 1.7 (1.20, 2.30) 0.003 
Glucose (mmol/L)* 5.6 (5.10, 6.50) 5.6 (5.10, 6.80) 0.12 
Creatinine (mmol/L) 99.09 (16.35) 102.43 (19.18) <0.0001 
CRP (mg/L)* 2.4 (1.21, 4.69) 3.0 (1.54, 5.53) <0.0001 
Diabetes 1002 (26.4%) 151 (30.9%) 0.03 
Metabolic Syndrome 1626 (42.8%) 221 (45.3%) 0.30 
FH CHD 687 (18.1%) 84 (17.2%) 0.63 
Amlodipine 1923 (50.6%) 230 (47.1%) 0.14 
Atorvastatin§ 1637 (51.3%) 103 (43.1%) 0.01 
  Table 2: Hazard ratios (95%CI) of cardiovascular event (CHD or Stroke) in relation to baseline CRP (per SD increase in Log-transformed CRP and in 
                 CRP tertiles) among all white subjects with no previous CVD  
 
Event/no-event Model1 P Model2 P 
CVD     
Lowest Tertile  106/1174 1.00 (Ref) 1.00 (Ref) 
Mid Tertile  160/1185 1.41 (1.11, 1.79) 0.01 1.45 (1.13, 1.87) 0004 
Highest Tertile 190/1172 1.75 (1.39, 2.20) <0.0001 1.51 (1.17, 1.94) 0.001 
Trend P<0.0001 P=0.002 
Log CRP per SD 456/3531 1.25 (1.15, 1.37) <0.0001 1.21 (1.09, 1.33) 0.0003 
CHD 
Lowest Tertile  75/1174 1.00 (Ref) 1.00 (Ref) 
Mid Tertile  114/1185 1.44 (1.09, 1.91) 0.01 1.46 (1.08, 1.96) 0.01 
Highest Tertile 145/1172 1.87 (1.43, 2.45) <0.0001 1.61 (1.20, 2.17) 0.002 
Trend P<0.0001 P=0.002 
Log CRP per SD 334/3531 1.32 (1.19, 1.46) <0.0001 1.27 (1.13, 1.43) <0.0001 
Stroke 
Lowest Tertile  31/1174 1.00 (Ref) 1.00 (Ref) 
Mid Tertile  46/1185 1.34 (0.86, 2.11) 0.2 1.55 (0.97, 2.47) 0.07 
Highest Tertile 45/1172 1.52 (0.98, 2.37) 0.06 1.40 (0.86, 2.28) 0.17 
Trend P=0.06 P=0.20 
Log CRP per SD 122/3531 1.12 (0.94, 1.33) 0.22 1.10 (0.91, 1.34) 0.32 
 
 Tertile: lowest: ≤1.42, mid: 1.43-3.46, highest: >3.46 mg/L 
 
Model 1: Adjusted for age and sex 
Model 2: Adjusted for age, sex, current smoking status, diabetes, baseline SBP, HDL, total cholesterol, randomised atenolol/amlodipine, randomised atorvastatin/placebo/not in LLA, 
                                   left ventricular hypertrophy, BMI, glucose, family history CHD, creatinine and educational attainment 
              
               
   
         Table 3: Association between CRP value above median at 6-month and CVD and CHD in relation to CRP of less than median value by atorvastatin and  
                      placebo  
    
 
 
 
 
  
 
 
 
 
 
 
 
 
 
  Median   value for atorvastatin group:  1.64 mg/L ; Placebo group:  2.24 mg/L 
      
  Model 1: Adjusted for age, sex and log baseline CRP 
  Model 2: Adjusted for age, sex, current smoking, diabetes, randomised BP treatment, left ventricular hypertrophy, baseline SBP, total cholesterol, HDL, BMI, glucose, 
                                                        Family history of CHD, creatinine, educational attainment, and loge baseline CRP 
    
 CVD  CHD 
Events/No event HR (95% CI) P Event/No event HR (95% CI) P
Model 1       
Atorvastatin       CRP<median 33/647 1.00 (Ref)  20/647 1.00 (Ref)  
                  CRP≥median 42/679 1.08(0.65,1.79) 0.78 34/679 1.27(0.69,2.35) 0.45 
Placebo             CRP<median 41/629 1.00 (Ref)  28/629 1.00 (Ref)  
                  CRP≥median 54/647 1.15(0.73,1.83) 0.54 41/647 1.26(0.73,2.16) 0.41 
Model 2   
Atorvastatin       CRP<median 33/647 1.00 (Ref)  20/647 1.00 (Ref)  
                  CRP≥median 42/679 1.06(0.63,1.79) 0.83 34/679 1.25(0.66,2.36) 0.49 
Placebo             CRP<median 41/629 1.00 (Ref)  28/629 1.00 (Ref)  
                  CRP≥median 54/647 1.21(0.75,1.95) 0.44 41/647 1.34(0.77,2.36) 0.30 
  
Table 4: Hazard ratios for CVD and CHD associated with achieved level of CRP or LDL-c at 6-month relative to placebo 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Among atorvastatin users, the median value for CRP at 6 month visit =1.64 mg/L;       LDL at 6 month visit = 2.12 mmol/L 
∆ = reduction  
          
 Model 1: Adjusted for age, sex and log baseline CRP 
 Model 2: Adjusted for age, sex, current smoking, diabetes, randomised BP treatment, left ventricular hypertrophy, baseline SBP, total cholesterol, HDL, BMI, glucose, 
                                                        Family history of CHD, creatinine, educational attainment, and loge baseline CRP 
 
Event/no event in LDL analyses: CVD: 91/1234, 44/639, 24/664, CHD: 66/1234, 33/639, 16/664
CVD CHD 
  
Events/ 
No event CRP P LDL P 
Events/ 
No event CRP P LDL P 
Model 1  
       Placebo 94/1251 1.00 (Ref) 1.00 (Ref) 68/1251 1.00 (Ref) 1.00 (Ref) 
       Atorvastatin:           
  ≥median 42/666 0.83(0.57,1.19) 0.30 0.93(0.65,1.33) 0.68 34/666 0.87(0.58,1.31) 0.50 0.88(0.58,1.33) 0.54 
< median 33/639 0.75(0.50,1.12) 0.16 0.52(0.33,0.83) 0.005 20/639 0.62(0.37,1.02) 0.06 0.49(0.28,0.85) 0.01 
< median vs≥ median  0.91(0.57,1.46) 0.70 0.56(0.34,0.94) 0.03  0.71(0.40,1.27) 0.25 0.56(0.30,1.03) 0.06 
  
Model 2   
       Placebo 94/1251 1.00 (Ref) 1.00 (Ref) 68/1251 1.00 (Ref) 1.00 (Ref) 
       Atorvastatin:           
  ≥median 42/666 0.81(0.56,1.18) 0.28 0.93(0.65,1.35) 0.72 34/666 0.88(0.57,1.34) 0.54 0.91(0.59,1.40) 0.67 
< median 33/639 0.78(0.52,1.17) 0.22 0.54(0.34,0.85) 0.008 20/639 0.66(0.40,1.09) 0.11 0.50(0.29,0.88) 0.02 
< median vs ≥ median  0.95(0.59,1.55) 0.85 0.58(0.34,0.97) 0.04  0.75(0.42,1.35) 0.34 0.55(0.30,1.03) 0.06 
           
       Placebo 94/1251 1.00(Ref)    68/1251 1.00(Ref)    
       Atorvastatin:           
∆% CRP< 24.34%¥ 48/846 0.70(0.47,1.05) 0.09   33/846 0.63(0.39,1.04) 0.07   
∆% CRP≥ 24.34% 43/651 0.88(0.61,1.28) 0.51   33/651 0.91(0.60,1.39) 0.67   
≥24.34% vs <24.34%   1.26(0.79,2.02) 0.34    1.44 (0.82,2.52) 0.20   
           
       Placebo 91/1234   1.00(Ref)  66/1234   1.00(Ref)  
       Atorvastatin:           
∆% LDL<39.34%¥ 57/833   0.81(0.54,1.20) 0.29 41/833   0.78(0.49,1.25) 0.31 
∆% LDL≥ 39.34% 34/664   0.68(0.46,1.02) 0.06 25/664   0.67(0.42,1.06) 0.09 
≥39.34% vs<39.34%     0.84(0.52,1.37) 0.49    0.85(0.48,1.50) 0.57 
  
Table 5: Hazard ratios for CVD and CHD associated with achieved level of CRP at 6-month relative to placebo using imputed data 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Among atorvastatin users, the median value for CRP at 6 month visit =1.69 mg/L (CVD) & 1.70mg/L (CHD);       LDL at 6 month visit = 2.13 mmol/L (CVD) & 2.12mmol/L (CHD) 
 
  ∆ = reduction 
 ¥   median value in atorvastatin group- CRP: 25.29% for CVD and 25.10% for CHD; LDL: 41.53% for CVD & 41.49% for CHD 
Event/no event in LDL analyses: CVD: 125/1556, 59/797, 38/841, CHD: 89/1556, 47/814, 22/824 
Model 1: Adjusted for age, sex and log baseline CRP 
 Model 2: Adjusted for age, sex, current smoking, diabetes, randomised BP treatment, left ventricular hypertrophy, baseline SBP, total cholesterol, HDL, BMI, glucose, 
                                                        Family history of CHD, creatinine, educational attainment, and loge baseline CRP 
CVD CHD 
  
Events/ 
No event CRP P LDL P 
Events/ 
No event CRP P LDL P 
Model 1   
      Placebo 125/1556 1.00 (Ref) 1.00 (Ref) 89/1556 1.00 (Ref) 1.00 (Ref) 
      Atorvastatin:           
               ≥median 58/812 0.87(0.63,1.20) 0.40 0.98(0.71,1.34) 0.88 47/814 0.94(0.64,1.36) 0.72 1.02(0.71, 1.47) 0.92 
           < median 39/826 0.64(0.44,0.92) 0.02 0.55(0.37,0.80) 0.002 22/824 0.56(0.36,0.88) 0.01 0.48(0.29,0.78) 0.003 
< median vs ≥  median  0.73(0.47,1.14) 0.16 0.56(0.36,0.88) 0.01  0.60(0.35,1.02) 0.06 0.47(0.27,0.83) 0.009 
  
Model 2   
      Placebo 125/1556 1.00 (Ref) 1.00 (Ref) 89/1556 1.00 (Ref) 1.00 (Ref) 
      Atorvastatin:           
               ≥median 58/812 0.80(0.57,1.11) 0.18 0.97(0.70,1.35) 0.86 44/817 0.81(0.55,1.19) 0.29 0.96(0.65,1.40) 0.82 
< median 39/826 0.70(0.48,1.02) 0.07 0.56(0.38,0.82) 0.003 25/821 0.61(0.39,0.98) 0.04 0.49(0.30,0.80) 0.005 
< median vs ≥  median  0.88(0.55,1.41) 0.59 0.57(0.36,0.91) 0.02  0.75(0.43,1.32) 0.32 0.51(0.28,0.92) 0.03 
           
      Placebo 125/1556 1.00 (Ref)    89/1556 1.00 (Ref)    
      Atorvastatin:           
∆% CRP< 25.29%¥ 43/832 0.72(0.50,1.03) 0.07   30/827 0.64(0.41,0.99) 0.045   
∆% CRP≥ 25.29% 54/806 0.78(0.56,1.09) 0.15   39/811 0.80(0.54,1.18) 0.26   
≥25.29% vs <25.29%  1.08(0.70, 1.69) 0.72    1.26(0.74,2.14) 0.40   
           
      Placebo 125/1556   1.00 (Ref)  89/1556   1.00 (Ref)  
      Atorvastatin:           
∆% LDL<41.53%¥ 52/821   0.90(0.64,1.25) 0.52 43/828   0.91(0.62,1.34) 0.64 
∆% LDL≥ 41.53% 45/817   0.62(0.43,0.90) 0.01 26/810   0.56(0.36,0.86) 0.009 
≥41.53% vs <41.53%    0.69(0.44,1.09) 0.11    0.61(0.36,1.02) 0.06 
  
Table 6: Hazard ratios for CVD and CHD according to achieved levels of CRP and LDL-cholesterol after 6-month atorvastatin 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Units used -  CRP:mg/L 
                LDL: mmol/L 
 
Adjusted for age, sex, current smoking, diabetes, randomised BP treatment, left ventricular hypertrophy, baseline SBP, HDL, 
                       BMI, glucose, Family history of CHD, creatinine, educational attainment, loge baseline CRP and LDL-c 
 
 
 
 
 
Events/ 
No-event 
CVD Events 
/No-event 
CHD 
HR (95% CI) P HR (95% CI) P 
Placebo 89/1175 1.00 (Ref)  64/1175 1.00 (Ref)  
CRP≥1.64 & LDL≥2.12 27/329 0.99(0.63,1.54) 0.96 25/329 1.18(0.73,1.90) 0.51 
CRP<1.64 & LDL ≥2.12 17/281 0.90(0.53,1.53) 0.69 8/281 0.57(0.27,1.20) 0.14 
CRP≥1.64 & LDL <2.12 12/302 0.56(0.30,1.03) 0.06 6/302 0.39(0.17,0.91) 0.03 
CRP<1.64 & LDL <2.12 12/331 0.55(0.30,1.02) 0.06 10/331 0.66(0.33,1.30) 0.23 
 
SUPPLEMENTAL MATERIAL 
 
 
 
Online Table 1: Age and sex adjusted Spearman correlation coefficients of baseline hsCRP with 
baseline clinical characteristics 
 
 
 
 
 
 
 
 
 
 
 
 
  
Non-event P-value Events P-value 
Age 0.0305 0.06 -0.0528 0.25 
Glucose 0.0300 0.078 0.0142 0.78 
Creatinine 0.0161 0.34 0.0970 0.041 
Total Cholesterol 0.0627 0.0002 0.1465 0.002 
LDL-c 0.0779 <0.0001 0.1622 0.0006 
Triglycerides 0.1520 <0.0001 0.1545 0.001 
HDL -0.1519 <0.0001 -0.1330 0.005 
BMI 0.2516 <0.0001 0.1686 0.0004 
SBP 0.0247 0.15 0.0048 0.92 
DBP -0.0105 0.54 0.0061 0.9 
Heart Rate 0.0764 <0.0001 0.0300 0.53 
 
     Online Table 2: Hazard ratios (95%CI) of cardiovascular event (CHD or Stroke) in relation to baseline CRP (per SD increase in Log-transformed CRP and in  
     CRP tertiles) among white subjects who were not on statin and with no previous CVD  
          
Events/Non-event Model 1 P Model 2 P 
CVD     
Lowest Tertile  87/684 1.00 (Ref)  1.00 (Ref)  
Mid Tertile  134/731 1.42 (1.08, 1.86) 0.01 1.44 (1.09, 1.92) 0.01 
Highest Tertile 164/745 1.68 (1.29, 2.19) <0.0001 1.56 (1.17, 2.07) 0.002 
Trend  P=0.0001 P=0.003 
     
Log CRP per SD 385/2160 1.25 (1.13, 1.39) <0.0001 1.21 (1.08, 1.36) 0.001 
 
CHD  
Lowest Tertile  65/684 1.00 (Ref)  1.00 (Ref)  
Mid Tertile  100/731 1.45 (1.06, 1.98) 0.02 1.45 (1.04, 2.02) 0.03 
Highest Tertile 121/745 1.75 (1.29, 2.36) <0.0001 1.64 (1.18, 2.29) 0.004 
Trend  P=0.0003 P=0.004 
     
Log CRP per SD 286/2160 1.29 (1.15, 1.46) <0.0001 1.26 (1.10, 1.44) 0.001 
 
CVA  
Lowest Tertile  22/684 1.00 (Ref)  1.00 (Ref)  
Mid Tertile  34/731 1.39 (0.81, 2.38) 0.23 1.50 (0.87, 2.59) 0.15 
Highest Tertile 43/745 1.63 (0.97, 2.74) 0.06 1.47 (0.84, 2.56) 0.18 
Trend  P=0.07 P=0.20 
     
Log CRP per SD 99/2160 1.18 (0.96, 1.45) 0.12 1.14 (0.91, 1.42) 0.25 
 
Model 1: Adjusted for age and sex 
Model 2: Adjusted for age, sex, current smoking status, diabetes, baseline SBP, HDL, total cholesterol, randomised atenolol/amlodipine, left ventricular hypertrophy, 
                   BMI, glucose, family history CHD, creatinine and educational attainment 
  Tertile: lowest: ≤1.42, mid: 1.43-3.46, highest: >3.46 mg/L 
 
Online Table 3. The risk of CVD and CHD in each tertile of baseline CRP in the atorvastatin-assigned group compared to the placebo group 
 
                        
 
 
 
 
  Adjusted for age, sex, current smoking status, diabetes, baseline SBP, HDL, total cholesterol, randomised atenolol/amlodipine, left ventricular hypertrophy, 
                   BMI, glucose, family history CHD, creatinine and educational attainment 
  * Interaction between statin treatment across tertile of baseline CRP 
 
 
 
 
  
 ORs (95% CI)by tertile of baseline CRP 
 Low Middle High Interaction* 
 
CVD 0.65 (0.38, 1.11) 0.88 (0.56, 1.40) 0.74 (0.49, 1.12) P=0.69 
     
CHD 0.59 (0.30, 1.14) 0.81 (0.46, 1.43) 0.77 (0.48, 1.23) P=0.74 
 
 
Online Table 4: Association between CRP value above median at 6-month and CVD and CHD in relation to CRP of less than median value by  
atorvastatin and placebo using imputed data  
 
  
 
 
 
 
 
 
 
 
 Relative to value at 6 month < median value within each category 
  Median   value for atorvastatin group:  1.69 mg/L (CVD); 1.70 mg/L (CHD) 
   Placebo group:  2.36 mmol/L; (CVD); 2.35 mmol/L (CHD) 
 
  Model 1: Adjusted for age & sex 
  Model 2: Adjusted for age, sex, current smoking, diabetes, randomised BP treatment, left ventricular hypertrophy, baseline SBP, total cholesterol, HDL, BMI, glucose, 
                                                        Family history of CHD, creatinine and educational attainment, and log baseline CRP 
 
 
 CVD  CHD 
Events/no-event HR (95% CI) P Event/no-event HR (95% CI) P
Model 1       
Atorvastatin      CRP<median 39/826 1.00 (Ref)  25/821 1.00 (Ref)  
                         CRP≥median 58/812 1.37(0.88,2.13) 0.16 44/817 1.65(0.97,2.80) 0.07 
       
Placebo           CRP<median 56/788 1.00 (Ref)  39/785 1.00 (Ref)  
                       CRP≥median 63/768 1.33(0.91,1.95) 0.15 50/771 1.35(0.86,2.13) 0.20 
       
Model 2   
Atorvastatin        CRP<median 39/826 1.00 (Ref)  25/821 1.00 (Ref)  
                   CRP ≥ median 58/812 1.15(0.68,1.93) 0.60 44/817 1.27(0.69,2.32) 0.44 
       
Placebo               CRP<median 56/788 1.00 (Ref)  39/785 1.00 (Ref)  
                 CRP≥median 63/768 1.24(0.78,1.97) 0.35 50/771 1.19(0.69,2.04) 0.53 
